Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2020

01-01-2020 | NSCLC | Original Article

Low paravertebral muscle mass in patients with bone metastases from lung cancer is associated with poor prognosis

Authors: Sho Dohzono, Ryuichi Sasaoka, Kiyohito Takamatsu, Masatoshi Hoshino, Hiroaki Nakamura

Published in: Supportive Care in Cancer | Issue 1/2020

Login to get access

Abstract

Purpose

Low skeletal muscle mass has been associated with poor prognosis in patients with advanced lung cancer. However, little is known about the relationship between skeletal muscle mass and overall survival in patients with bone metastases from lung cancer. The objective of the present study was to evaluate the prognostic value of low trunk muscle mass in predicting overall survival in these patients.

Methods

The data from 198 patients who were diagnosed with bone metastases from lung cancer from April 2009 to May 2017 were retrospectively reviewed. The areas of the psoas and paravertebral muscles were measured at the level of the third lumbar vertebra on computed tomography scans taken at the time nearest to the diagnosis of bone metastasis. Muscle area was evaluated for male and female cohorts separately using different cutoff points. Cox proportional hazards analysis was performed to evaluate the factors independently associated with overall survival.

Results

The overall survival of patients in the lowest quartile for psoas muscle area or paravertebral muscle area was significantly shorter than that of patients above the 25th percentile for muscle area (p < 0.001). Multivariate analyses showed that paravertebral muscle mass (hazard ratio, 1.73; 95% confidence interval, 1.17–2.56; p = 0.006), epidermal growth factor receptor-targeted therapy, and performance status were independent prognostic factors.

Conclusions

Low paravertebral muscle mass was associated with shorter survival, independently of known prognostic factors.
Literature
1.
Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA (2009) Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251–259CrossRef
2.
Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW, Heo DS (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 77:572–577CrossRef
3.
Bauer H, Tomita K, Kawahara N, Abdel-Wanis ME, Murakami H (2002) Surgical strategy for spinal metastases. Spine 27:1124–1126CrossRef
4.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRef
5.
Brodowicz T, O'Byrne K, Manegold C (2012) Bone matters in lung cancer. Ann Oncol 23:2215–2222CrossRef
6.
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRef
7.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423CrossRef
8.
Gakhar H, Dhillon A, Blackwell J, Hussain K, Bommireddy R, Klezl Z, Williams J (2015) Study investigating the role of skeletal muscle mass estimation in metastatic spinal cord compression. Eur Spine J 24:2150–2155CrossRef
9.
Go SI, Park MJ, Song HN, Kang MH, Park HJ, Jeon KN, Kim SH, Kim MJ, Kang JH, Lee GW (2016) Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Support Care Cancer 24:2075–2084CrossRef
10.
Katagiri H, Okada R, Takagi T, Takahashi M, Murata H, Harada H, Nishimura T, Asakura H, Ogawa H (2014) New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 3:1359–1367CrossRef
11.
Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, Hisamatsu Y, Tokito T, Imai H, Akamatsu H, Ono A, Kaira K, Murakami H, Endo M, Mori K, Takahashi T, Yamamoto N (2015) Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23:1699–1708CrossRef
12.
Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P (2015) The incidence and clinical impact of bone metastases in non-small cell lung cancer. Lung Cancer 89:197–202CrossRef
13.
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539–1547CrossRef
14.
Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006CrossRef
15.
Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635CrossRef
16.
Rades D, Douglas S, Veninga T, Schild SE (2012) A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer 12:302CrossRef
17.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRef
18.
Rief H, Omlor G, Akbar M, Welzel T, Bruckner T, Rieken S, Haefner MF, Schlampp I, Gioules A, Habermehl D, von Nettelbladt F, Debus J (2014) Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 14:67CrossRef
19.
Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127:990S–991SCrossRef
20.
Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97:2333–2338CrossRef
21.
Sjoblom B, Benth JS, Gronberg BH, Baracos VE, Sawyer MB, Flotten O, Hjermstad MJ, Aass N, Jordhoy M (2017) Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer 18:e129–e136CrossRef
22.
Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729–736CrossRef
23.
Takayama K, Kita T, Nakamura H, Kanematsu F, Yasunami T, Sakanaka H, Yamano Y (2016) New predictive index for lumbar paraspinal muscle degeneration associated with aging. Spine 41:E84–E90CrossRef
24.
Tan JH, Tan KA, Zaw AS, Thomas AC, Hey HW, Soo RA, Kumar N (2016) Evaluation of scoring systems and prognostic factors in patients with spinal metastases from lung Cancer. Spine 41:638–644CrossRef
25.
Tang V, Harvey D, Park Dorsay J, Jiang S, Rathbone MP (2007) Prognostic indicators in metastatic spinal cord compression: using functional independence measure and Tokuhashi scale to optimize rehabilitation planning. Spinal Cord 45:671–677CrossRef
26.
Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J (2005) A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 30:2186–2191CrossRef
27.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef
28.
Wang C, Bai L (2012) Sarcopenia in the elderly: basic and clinical issues. Geriatr Gerontol Int 12:388–396CrossRef
29.
Zakaria HM, Basheer A, Boyce-Fappiano D, Elibe E, Schultz L, Lee I, Siddiqui F, Griffith B, Chang V (2016) Application of morphometric analysis to patients with lung cancer metastasis to the spine: a clinical study. Neurosurg Focus 41:E12CrossRef
Metadata
Title
Low paravertebral muscle mass in patients with bone metastases from lung cancer is associated with poor prognosis
Authors
Sho Dohzono
Ryuichi Sasaoka
Kiyohito Takamatsu
Masatoshi Hoshino
Hiroaki Nakamura
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04843-9

Other articles of this Issue 1/2020

Supportive Care in Cancer 1/2020 Go to the issue

Original Article

Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis

Original Article

The risk of bloodstream infection associated with totally implantable venous access ports in cancer patient: a systematic review and meta-analysis

Original Article

Ventilator-associated pneumonia and bloodstream infections in intensive care unit cancer patients: a retrospective 12-year study on 3388 prospectively monitored patients

Original Article

A survey of oncology healthcare professionals’ knowledge and attitudes toward the use of music as a therapeutic tool in healthcare

Original Article

Symptom correlates of dyspnea in advanced cancer patients using the Edmonton Symptom Assessment System

Original Article

CancerSupportSource®: validation of a revised multi-dimensional distress screening program for cancer patients and survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits